Blood Peptidome-Degradome Profile of Breast Cancer

Background Cancer invasion and metastasis are closely associated with activities within the degradome; however, little is known about whether these activities can be detected in the blood of cancer patients. Methodology and Principal Findings The peptidome-degradome profiles of pooled blood plasma sampled from 15 breast cancer patients (BCP) and age, race, and menopausal status matched control healthy persons (HP) were globally characterized using advanced comprehensive separations combined with tandem Fourier transform mass spectrometry and new data analysis approaches that facilitated top-down peptidomic analysis. The BCP pool displayed 71 degradome protein substrates that encompassed 839 distinct peptidome peptides. In contrast, the HP 50 degradome substrates found encompassed 425 peptides. We find that the ratios of the peptidome peptide relative abundances can vary as much as >4000 fold between BCP and HP. The experimental results also show differential degradation of substrates in the BCP sample in their functional domains, including the proteolytic and inhibitory sites of the plasmin-antiplasmin and thrombin-antithrombin systems, the main chains of the extracellular matrix protection proteins, the excessive degradation of innate immune system key convertases and membrane attack complex components, as well as several other cancer suppressor proteins. Conclusions Degradomics-peptidomics profiling of blood plasma is highly sensitive to changes not evidenced by conventional bottom-up proteomics and potentially provides unique signatures of possible diagnostic utility.

[1]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[2]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[3]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[4]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[5]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[6]  Ronald J. Moore,et al.  Making broad proteome protein measurements in 1-5 min using high-speed RPLC separations and high-accuracy mass measurements. , 2005, Analytical chemistry.

[7]  Ronald J Moore,et al.  Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. , 2004, Analytical chemistry.

[8]  K. Honn,et al.  Thrombin increases the metastatic potential of tumor cells , 1993, International journal of cancer.

[9]  Ch.B. F.R.C.P. David V. Schapira M.B.,et al.  Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer , 2005, Breast Cancer Research and Treatment.

[10]  Steven Patierno,et al.  Tissue factor, thrombin, and cancer. , 2003, Chest.

[11]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[12]  Nikola Tolić,et al.  Targeted comparative proteomics by liquid chromatography-tandem Fourier ion cyclotron resonance mass spectrometry. , 2005, Analytical chemistry.

[13]  C. López-Otín,et al.  Protease degradomics: A new challenge for proteomics , 2002, Nature Reviews Molecular Cell Biology.

[14]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  I. G. Shvyrkova,et al.  Proteolytic specificity of plasmin toward adhesive proteins , 2000, Russian Journal of Bioorganic Chemistry.

[16]  Wiklund Ra,et al.  First of two parts , 1997 .

[17]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[18]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[19]  M. Walport Complement. First of two parts. , 2001, The New England journal of medicine.

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  Timothy D. Veenstra,et al.  AN ACCURATE MASS TAG STRATEGY FOR QUANTITATIVE AND HIGH THROUGHPUT PROTEOME MEASUREMENTS , 2002 .

[22]  Bonnie F. Sloane,et al.  Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[23]  E. Davie,et al.  Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. , 1990, The Journal of biological chemistry.

[24]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Petricoin,et al.  The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.

[26]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[27]  D. Ankerst,et al.  Afamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[28]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[29]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[30]  H. Rus,et al.  Persistent complement activation on tumor cells in breast cancer. , 1992, The American journal of pathology.

[31]  F. Bost,et al.  Inter-alpha-trypsin inhibitor proteoglycan family--a group of proteins binding and stabilizing the extracellular matrix. , 1998, European journal of biochemistry.

[32]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[33]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[34]  John D Lambris,et al.  Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.

[35]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[36]  Wei Li,et al.  Biochemical Characterization and Function of Complexes Formed by Hyaluronan and the Heavy Chains of Inter-α-inhibitor (HC·HA) Purified from Extracts of Human Amniotic Membrane* , 2009, The Journal of Biological Chemistry.

[37]  Ronald J Moore,et al.  Strategy for degradomic-peptidomic analysis of human blood plasma. , 2010, Journal of proteome research.

[38]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[39]  Yan Dong,et al.  Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells. , 2002, Experimental cell research.

[40]  Richard D. Smith,et al.  Identification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approach. , 2010, Journal of proteome research.

[41]  Piet Gros,et al.  Structure of C3b reveals conformational changes that underlie complement activity , 2006, Nature.

[42]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[43]  J. Enghild,et al.  The Transfer of Heavy Chains from Bikunin Proteins to Hyaluronan Requires Both TSG-6 and HC2* , 2008, Journal of Biological Chemistry.

[44]  J. Potempa,et al.  Alpha-2-antiplasmin: a serpin with two separate but overlapping reactive sites. , 1988, Science.

[45]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.